Patients must have recovered from all clinically relevant adverse events to grade  or baseline due to previous agents administered (except alopecia)
Patients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >=  weeks prior to entering the study and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least  weeks prior to entering the study; patients must have discontinued radiation therapy >=  weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >=  weeks from registration and patients must be fully recovered from post-surgical complications
Prior Therapy:\r\n* Patients must have had no prior anthracycline (e.g., doxorubicin, daunorubicin) or ifosfamide chemotherapy\r\n* Patients must have had no prior use of pazopanib or similar multi-targeted tyrosine kinase inhibitors (TKI)\r\n* Patients must have had no prior radiotherapy to tumor-involved sites\r\n* Note: patients previously treated for a non-NRSTS cancer are eligible provided they meet the prior therapy requirements; patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier are excluded
Participants who have had anti-cancer therapy within  weeks prior to entering the study or those who have not recovered from acute adverse events due to agents administered more than  weeks earlier; palliative radiation to bony metastases >=  weeks prior to study entry is allowed; chronic use (defined as starting at least  months prior to registration) of GnRH agonist therapy, such as leuprorelin, at the time of study entry is not exclusionary and participants can continue the GnRH agonist therapy while on study
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C), immunotherapy within  weeks, targeted therapies (e.g. small molecule inhibitors such as pazopanib) within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; not clinically significant or clinically stable adverse events from prior therapy (e.g. immunotherapy related hypothyroidism or insulin-dependent diabetes stable on medication or tyrosine kinase inhibitor [TKI]-related hypertension or rash etc.) is allowed
Participants who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from acute effects of any prior therapy to baseline or grade =<  except for alopecia or adverse events (AEs) not constituting a safety risk in the opinion of the investigator
Participants who have received prior systemic therapy (chemotherapy or targeted therapy) within  days of Study Day  or those who have not recovered from clinically significant adverse events due to agents administered more than  days earlier. (continuation of the same regimen of HER- antibody targeted therapy agents, hormonal therapy and treatment with bisphosphonates or denosumab are permitted)
Patient has not recovered from adverse events due to chemotherapy, immunotherapy, or radiation therapy administered more than  days prior to first administration of study drug.
Prior treatments:\r\n* Patients who have had systemic cytotoxic therapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) or targeted therapy with small molecule inhibitors within  weeks prior to entering the study\r\n* Patients who have not recovered from adverse events (=< grade ; except alopecia) due to agents administered more than  weeks earlier\r\n* Patients need to be free of adverse effects (=< grade ; except alopecia) from prior treatments for at least  days from cycle  day  of PLX and sirolimus
Chemotherapy, radioactive, or biological cancer therapy within  weeks prior to the first dose of study drug, or not recovered from clinically significant adverse events due to cancer therapeutics administered more than  weeks prior to the first dose of study drug
Patients with incomplete recovery from adverse events due to agents administered more than  weeks prior to registration are not eligible
Patients must have recovered to grade  or baseline from adverse events (AEs) and/or toxicity of prior chemotherapy or biologic therapy; they must not have had chemotherapy, biologic therapy, or definitive radiotherapy within  weeks ( weeks for nitrosoureas and mitomycin C) or  half-lives, whichever is shorter, prior to entering the study; palliative-intent radiotherapy ( Gy or less) must be completed at least  weeks prior to start of treatment, and may not be to a lesion that is included as measurable disease; patients must be >=  weeks since any investigational agent administered as part of a phase  study (where a sub-therapeutic dose of drug is administered) at the principal investigator's (PIs) discretion, and should have recovered to grade  or baseline from any toxicities
Has had chemotherapy, definitive radiation, or biological cancer therapy within  weeks prior to the first dose of study drug, or has not recovered to Baseline or CTCAE grade  from the adverse events due to cancer therapeutics administered > weeks earlier.
Participants who have not recovered to eligibility levels from adverse events due to agents administered prior to study entry
Participants who have had chemotherapy, targeted therapies, radiotherapy, or used an investigational device within  weeks prior to the first dose of treatment or those who have not recovered from adverse events (i.e., =< grade  or at baseline) due to agents administered more than  weeks earlier; note: participants with =< grade  neuropathy are an exception to this criterion and may qualify for the study
Has had prior chemoembolization, bland embolization, radioembolization, local ablative therapies, radiation to liver tumors, or major surgery such as liver resection within  weeks prior to study enrollment or who has not recovered (i.e., =< grade  or at baseline) from adverse events due to intervention more than  weeks earlier
The patient has not recovered to grade ?  from adverse events (AEs) due to investigational drugs or other medications, which were administered more than  weeks prior to the first dose of study drug.
Participants who have had chemotherapy (not including molecularly targeted agents; examples include, but are\r\nnot limited to, tyrosine kinase inhibitors (such as FLT inhibitors) and IDH inhibitors), radiation treatment and/or surgery  weeks prior to entering the study. Those who have not recovered sufficiently from adverse events due to agents administered more than  weeks earlier are also ineligible
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered (Common Terminology Criteria for Adverse Events [CTCAE] v. grade =< ) from adverse events due to agents administered more than  weeks earlier, unless those events are deemed to have returned to baseline, are\r\nirreversible, or are unlikely to develop into a life-threatening condition at the permission of the protocol chair (e.g., alopecia); hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration
Patients who have had immunotherapy or radiotherapy within  weeks prior to study treatment or those who have not recovered from adverse events due to agents administered more than  weeks prior to study treatment; prior history of palliative radiation for symptomatic bony or brain metastases is permissible
Patients may have had one or more prior therapies; prior therapy should have completed within  weeks ( weeks for nitrosoureas or mitomycin C,  half-lives for targeted therapies) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; concurrent palliative radiotherapy is allowed at the discretion of the treating physician
Participants who have had anti-tumor therapy or other investigational agents within  weeks prior to registration ( weeks for nitrosoureas or mitomycin C), or those who have not recovered from adverse events due to agents administered more than  weeks prior to registration
Patients have received prior chemotherapy or radiation for AML < two weeks before study enrollment, or those who have not recovered from the adverse events due to agents administered
Chemotherapy or radiotherapy within  weeks (or targeted therapies  half-lives) prior to entering the study, or failure to recover from adverse events due to agents administered to =< grade  or stable grade , at the discretion of the treating physician
Patients who have had cytotoxic anticancer chemotherapy or immune checkpoint inhibitor within  weeks ( weeks for nitrosoureas or mitomycin C) or palliative radiation within  weeks (stereotactic radiation therapy [SRS] for brain metastasis within  hours) prior to entering the study or those who have not recovered from adverse events (>= grade ) due to agents administered more than  weeks earlier
Patients who have not recovered to =< grade  from adverse events due to agents administered >=  days prior to registration are not eligible
Previous cytotoxic chemotherapy must have been completed at least  weeks and radiotherapy at least  weeks prior to day  of treatment on the study, and all adverse events (excluding alopecia) due to agents administered more than  weeks earlier should have recovered to < grade ; participants with hematologic malignancies are expected to have hematologic abnormalities at study entry; hematologic abnormalities that are thought to be primarily related to leukemia are not considered to be toxicities (adverse events [AE]) and do not need to resolve to < grade 
Must have completely recovered or recovered to baseline prior to screening from any prior adverse events (AEs) occurring while receiving prior immunotherapy.
Prior chemotherapy <  weeks prior to study drug treatment and treatment related adverse events that have not recovered to baseline or grade  (alopecia excluded); prior radiation therapy <  weeks prior to study drug treatment
Subjects who have received investigational or approved oral or targeted agents (such as spleen tyrosine kinase [SYK], phosphatidylinositol  kinase [PIK], B-cell chronic lymphocytic leukemia [CLL]/lymphoma  [bcl-], BTK inhibitors) or lenalidomide within  week prior to entering the study or those whose adverse events due to agents administered more than  week earlier have not recovered to =< grade ; this excludes hematologic adverse events
Subject has received any of the following:\r\n* Chemotherapy, biological therapy, or surgery within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks prior to on-study date\r\n* Radiation therapy, within  weeks prior to entering the study or those who have not recovered from adverse events due to radiation administered more than  weeks prior to on-study date\r\n* Prior therapy with bevacizumab\r\n* Prior therapy with an anti-programed cell death  (PD-), anti-programed cell death -ligand (PD-L), anti-PD-L, anti-cluster of differentiation (CD), or anti-cytotoxic T-lymphocyte-associated antigen- (CTLA-) antibody\r\n* Prior treatment with an HDAC inhibitor, with the exception of prior or current treatment with valproate\r\n* Any investigational agents or have had any investigational agent within the  days prior to on-study date\r\n* A live vaccine within  days prior to on-study date\r\n* Previous treatment with carmustine wafer except when administered as first line treatment and at least  months prior to on-study date
Patient who has had chemotherapy or exposure to a CDK / inhibitor within  weeks ( weeks for nitrosoureas, mitomycin C or bevacizumab) who has not recovered from the adverse events due to previous agents administered more than  weeks prior to study day ; hormonal therapy must be discontinued at least  hours prior to starting study treatment
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier\r\n* For Part I, prior adjuvant therapy with gemcitabine or a fluoropyrimidine therapy is permitted if completed >  months prior to recurrence; no prior PARP inhibitor therapy is allowed\r\n* For Part II, no prior PARP inhibitor therapy is permitted; up to two prior treatment regimens are permitted as follows:  adjuvant and  metastatic;  locally advanced and  metastatic; or  metastatic, or a variation thereof
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients may not have had hormonal therapy within  weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions
Patients who have received systemic cytotoxic chemotherapy or approved oral targeted therapy or immunotherapy for  weeks, or other investigational agents for  weeks ( half-lives for any oral targeted agents), or radiotherapy to a non-brain site for  weeks before initiation of IPdR therapy; patients who have recovered from serious (Common Terminology Criteria for Adverse Events [CTCAE] grade  or more higher) to grade  or less adverse events from the previous therapies are eligible; prior/current/future hormonal therapy and/or bisphosphonates are permitted with no minimum interval to initiation of study therapy; if indicated, patients can receive palliative radiation therapy to a non-brain site concurrent or immediately post-study treatment with no minimum interval to initiation of study therapy
Patients must have completed any chemotherapy, radiation therapy, or biologic therapy >=  weeks prior to entering the study; patients must be >=  weeks since any prior administration of a study drug in a phase  or equivalent study; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permitted
Patients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting >=  weeks prior to randomization and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least  weeks prior to entering the study; patients must have discontinued radiation therapy >=  weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be >=  weeks from randomization and patients must be fully recovered from post-surgical complications
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse event due to agents administered more than  weeks earlier have not resolved or stabilized; patients who have been administered ABT- as part of a single or combination, phase  or I study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-
Patients who have had systemic (IV) cytotoxic chemotherapy or any other investigational agents within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; if a patient received an oral agent, treatment on study cannot commence at least five half-lives of the agent have elapsed
DOSE ESCALATION COHORT: Patient has received chemotherapy within  weeks prior to entering the study or has not recovered sufficiently (i.e., greater than grade ; PI will judge patient recovery status) from adverse events due to agents administered more than  weeks earlier; exceptions are stable chronic toxicities not expected to resolve, such as peripheral neurotoxicity, alopecia, and fatigue
DOSE EXPANSION COHORT: Patient has received chemotherapy within  weeks prior to entering the study or has not recovered sufficiently (i.e., greater than grade , PI will judge patient recovery status) from adverse events due to agents administered more than  weeks earlier; exceptions are stable chronic toxicities not expected to resolve, such as peripheral neurotoxicity, alopecia, and fatigue
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those whose adverse events have not resolved to grade  or less (except alopecia) from agents administered more than  weeks earlier; patients must have completed prior biological therapies and/or targeted therapies >=  weeks prior to study enrollment; patients who have had radiation to the pelvis or other bone marrow-bearing sites will be considered on a case by case basis and may be excluded if the bone marrow reserve is not considered adequate (i.e. radiation to > % of bone marrow)
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) of starting treatment or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients may not have had hormonal therapy within  weeks prior to entering the study; patients receiving raloxifene for bone health as per Food and Drug Administration (FDA) indication may remain on raloxifene absent other drug interactions
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than  weeks earlier; patients who have had prior pelvic radiation may be at increased risk for bowel perforation, and therefore may not have residual inflammatory disease of the bowel or residual bowel toxicity based on baseline imaging and clinical assessment; palliative (limited-field) radiation therapy is permitted, if all of the following criteria are met:\r\n* Repeat imaging demonstrates no new sites of bone metastases\r\n* The lesion being considered for palliative radiation is not a target lesion\r\n* Bowel toxicity is not expected from the target field due to increased risk of perforation
Previous cytotoxic chemotherapy must have been completed at least  weeks and radiotherapy at least  weeks prior to day  of treatment on the study and all adverse events (excluding alopecia, acne, rash) due to agents administered more than  weeks earlier should have recovered to =< grade ; patients with hematologic malignancies are expected to have hematologic abnormalities at study entry; these abnormalities which are thought to be primarily related to the underlying leukemia, are not considered to be toxicities (adverse event [AE]) and do not need to resolve to =< grade 
Patients who have had chemotherapy within  week ( weeks for nitrosoureas or mitomycin C) or investigational therapies/monoclonal antibodies within  half-life of investigational compound or those who have adverse events which are greater than grade  and are due to agents administered more than  week earlier; bisphosphonates, endocrine therapy, and trastuzumab are permitted without restriction
Patients who have had chemotherapy or radiotherapy within  weeks, or topical therapy within  weeks prior to initiating protocol therapy or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients are allowed to take weak potency topical corticosteroids if patient has been on a stable dose for more than a month
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; there will be at least a  week delay from the time of a previous bladder biopsy/transurethral resection of bladder tumor (TURBT) to allow for adequate bladder healing prior to enrollment
Patients must have discontinued cytotoxic therapy agents at least  weeks, cytokine based immunotherapy at least  weeks and immunoregulatory antibody therapy at least  weeks prior to entering the study and have recovered from adverse events due to those agents
For patients who have received gamma knife or stereotactic radiosurgery, a  week washout is required; patients who have had other types of radiotherapy, chemotherapy or biologic agents within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier to =< grade ; at least  weeks must have elapsed since any major surgery; patients with prostate cancer may continue to receive hormonal therapy
Patients who have received systemic cytotoxic chemotherapy, immunotherapy for  weeks before initiation of planned WBRT or patients who have not recovered from serious (Common Terminology Criteria for Adverse Events [CTCAE] grade  or more) adverse events from the previously received agents; for oral targeted agents or any other investigational agents, at least  half-lives of the agent ( weeks for nitrosoureas or mitomycin C) should have elapsed prior to starting study treatment
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients who have been administered ABT- as part of a single or limited dosing study, such as a phase  study, should not necessarily be excluded from participating in this study solely because of receiving prior ABT-
Subjects who have had chemotherapy or radiotherapy or any systemic therapy for melanoma within  weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; no concomitant therapy is allowed including IL, interferon, ipilimumab, anti-PD- or anti-PD-L antibody, cytotoxic chemotherapy, immunosuppressive agents, or other investigational therapies
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events (AEs) due to agents administered more than  weeks earlier (i.e., grade >=  AE present); palliative (limited-field) radiation therapy is permitted, as long as the lesion being considered for palliative radiation is not a target lesion
Patients receiving chemotherapy or radiotherapy within  weeks of injection of HF, or history of Grade  adverse events or presence of adverse events Grade  or greater, except alopecia, resulting from anticancer agents administered more than  weeks prior to HF injection.
Patients who have had chemotherapy for the treatment of the advanced or unresectable urothelial cancer of the bladder are not eligible; patients who were previously treated for local disease must not have received radiotherapy or chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study and must have recovered from adverse events due to agents administered more than  weeks earlier; patients who have received neoadjuvant or adjuvant chemotherapy must have completed treatment at least  months prior to diagnosis of metastatic disease
Has received treatment with radiation therapy, surgery, chemotherapy, or an investigational agent within  weeks prior to registration, ( weeks for radiation therapy, radionuclides, nitrosoureas, or mitomycin C) or who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; steroids used for disease related symptoms should be stopped within  hours of protocol therapy; patients who have had prior exposure to a Brutons tyrosine kinase (BTK) inhibitor; patients who received monoclonal antibody =<  weeks prior to first administration of study treatment
Prior chemotherapy or targeted therapy (including any investigational agents) within  weeks prior entering the study or those who have not recovered adequately from adverse events (AEs) due to agents administered more than  weeks earlier (excluding alopecia and hot flashes); a washout period is not necessary for trastuzumab or pertuzumab, hormone therapy, or radiation therapy
Receipt of radiation therapy within  weeks prior to entering the study, or lack of recovery from adverse events to grade  or less due to radiation administered more than  weeks earlier
Patients who have had systemic chemotherapies or targeted therapies within  weeks or radiotherapy within  weeks prior to entering the study or those patients whose adverse events from prior therapies have not recovered to =< grade  (other than grade  neuropathy, lymphopenia and alopecia which are permitted)
Patients who have had chemotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; prior radiation treatment to the target vestibular schwannoma is allowed if provided  years prior to participation in the clinical trial; prior radiation treatment to non-target tumors is allowed
Patients who have had myeloma therapy within  days prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients may have received bisphosphonate therapy or radiation therapy as part of routine myeloma care at any time prior to study entry
Patient who has had chemotherapy, radiotherapy, or hormonal therapy within  weeks ( weeks for nitrosoureas, mitomycin C or bevacizumab), or who has not recovered from the adverse events due to previous agents administered more than  weeks prior to Study Day ; if the patient has residual toxicity from prior treatment, toxicity must be =< Grade 
Received prior TKI treatment within  days prior to receiving the first dose of ponatinib, or have not recovered from adverse events (except alopecia) due to agents previously administered.
Patients who receive other chemotherapy; patients must have been off previous therapy for >=  weeks and must have recovered from clinically significant toxicity (to grade  or less) of all previous therapy prior to enrollment (consent signing) with the following exceptions: steroids, hydroxyurea, oral mercaptopurine, methotrexate, vincristine (including prophylactic intrathecal medication), thioguanine, and tyrosine kinase inhibitors are permitted within  weeks of randomization as maintenance or to reduce the peripheral blood blast counts; during ibrutinib therapy, only steroids and hydroxyurea are permitted to reduce peripheral blood blast counts; patients who have had chemotherapy or radiotherapy within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients who have had chemotherapy (including targeted therapy i.e. cetuximab, panitumumab) or radiotherapy =<  weeks or treatment with bevacizumab =<  weeks prior to entering the study or those who have not recovered from acute adverse events due to agents administered more than  weeks earlier, with the exclusion of alopecia or neuropathy; patients with history of radiation to the liver including radio-labeled microspheres at any point in their past will be excluded
Patients receiving immunotherapy, hormonal-therapy and or radiotherapy within  weeks prior to entering the study; Note: those who have not recovered from adverse events due to these agents administered will be considered ineligible
Participants who have had anti-neoplastic treatment for KS (including chemotherapy, radiotherapy, local treatment including topical fluorouracil [-FU], biological therapy or investigational therapy) within  weeks ( weeks for nitrosoureas or mitomycin C) prior to entering the study OR those who have not recovered from adverse events due to agents administered more than  weeks earlier
Patients must not have received systemic therapy or radiotherapy within the preceding  weeks; patients must have recovered from adverse events from previous therapy by the time of registration
Patients who have had systemic therapy for melanoma or radiotherapy within  weeks prior to registering on the study or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients with a history of endocrinopathies (e.g. hypothyroidism, adrenal insufficiency, hypopituitarism) are eligible if they are stable on hormone replacement therapy
Patients who have had anticancer therapy, including kinase inhibitors or any investigational agent within  weeks or  half-lives (whichever is shorter) ( weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered to baseline from adverse events (except alopecia and other non-clinically significant adverse events [AEs]); patients who have received prior cabozantinib or inhibitors of c-MET or HGF are ineligible
Any of the following:\r\n* Chemotherapy =<  weeks prior to entering the study ( weeks for nitrosoureas or mitomycin C)\r\n* Radiotherapy, endocrine therapy or targeted therapy for malignancy =<  weeks prior to registration\r\n* Patients who have not recovered (=< grade ) from adverse events due to agents administered more than  weeks earlier (tolerable grade  adverse events may be allowed at the discretion of the investigator; diarrhea must be grade  or lower without the scheduled use of antidiarrheal medications)\r\n* Prior anticancer therapy with an mammalian target of rapamycin (mTOR) inhibitor (everolimus, temsirolimus, desferolimus) or agent specifically targeting c-Met
Patients who have not recovered from adverse events due to prior agents; a minimum interval of  weeks should have elapsed from prior radiotherapy and/or chemotherapy
The participant has not recovered to Grade ?  from adverse events due to agents administered more than  weeks prior to study entry (except for alopecia)
Patients who have had chemotherapy or extra-cranial radiotherapy within  weeks prior to study screening or those who have not recovered from adverse events due to agents administered more than  weeks prior to the completion of study screening
Prior radiation therapy to a symptomatic site of metastatic disease is allowed but patients must have discontinued/completed radiation therapy at least  weeks prior to entering the study, and have recovered from adverse events due to that treatment
Have not recovered from adverse events due to other pharmaceutical or diagnostic agents.
The patient has not recovered to grade ?  adverse events (AEs) due to investigational drugs or other medications, administered more than  weeks prior to the first dose of study drug, with the exception of neurotoxicity attributed to oxaliplatin or taxanes, which must have recovered to <  prior to study initiation.